壽康集團: Fortacin™╱Senstend™中國第三期隨機臨床試驗取得十分優秀的成果
Retrieved on:
星期一, 四月 17, 2023
Compared to both baseline and placebo, Senstend(TM) produced clinically and statistically significant increases in IELT, ejaculatory control and satisfaction and reduction in distress.